Chemed Corporation (CHE) Presents at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Transcript

Management said they are "very comfortable" with VITAS guidance and believe it may be conservative, citing a shift back to a more balanced short- and long-stay patient mix that could provide upside through 2026. The CFO also expressed confidence in Roto-Rooter guidance despite noting the business had been weak in recent years and frequently missed early-year expectations. No specific financial revisions or quantitative guidance changes were announced during the discussion.

Analysis

Chemed’s multi‑segment structure creates a convexity opportunity: hospice (VITAS) upside from patient‑mix normalization can show up as outsized revenue per admission over several quarters while Roto‑Rooter’s operational leverage amplifies any sequential recovery in service volumes and pricing. Expect material P&L sensitivity to a ~1–3ppt swing in occupancy/route density — that’s the mechanical channel that could turn a mildly positive guidance skew into a double‑digit EPS surprise within 2–4 quarters.

Near‑term catalysts are operational (route density, technician utilization, and patient length‑of‑stay mix) rather than macro only, so monitor weekly/biweekly operational KPIs and SSS‑like prints in quarterly commentary. Regulatory tail risk — Medicare payment tweaks or focused audits — is low‑probability but high‑impact and would compress multiples quickly; that risk sits on a 6–24 month horizon and argues for option overlays rather than naked exposure.

Second‑order winners if Chemed executes: regional hospice providers (M&A targets) and service staffing vendors, because an active M&A cadence would push valuations for comp assets higher and create buyout arbitrage. Conversely, private, fragmented local plumbing peers lose pricing power as Roto‑Rooter leverages national pricing, technology (routing), and supply contracts to widen competitive moat over 12–18 months.

Consensus underestimates how rapidly operating gearing can flip outcomes: the market is over‑discounting Roto‑Rooter near‑term misses and underpricing the upside from a modest restoration of patient mix at VITAS. That asymmetry favors defined‑risk bullish exposure sized to survive a regulatory shock while capturing operational improvement across 2–4 quarters.

Key Decisions for Investors

• Initiate a tactical long in CHE (3% NAV) with a 6–12 month horizon to capture VITAS patient‑mix normalization and Roto‑Rooter route density recovery; set a discipline to trim 50% of the position on a 20–30% price move higher and a hard stop at -15% to limit regulatory downside.
• Buy a 12–15% cost‑effective upside call spread (LEAP) on CHE expiring 12–18 months out to get asymmetric payoff: target ~2–3x upside if operational KPIs improve, with max loss limited to premium paid — use spreads to avoid sharp theta decay risk.
• Establish a collar on an existing CHE holding: sell near‑term (3–6 month) 15–20% OTM calls to finance 12–18 month 10–15% OTM protective puts, balancing cost while protecting against a surprise Medicare/audit shock.
• Event‑driven alert: accumulate into weakness ahead of quarterly updates if management upgrades KPIs (route productivity or median patient length‑of‑stay) or announces tuck‑in M&A — these are the most likely near‑term re‑rating triggers within 2–4 quarters.
• Avoid naked leverage. If seeking higher conviction, pair long CHE with a small short of regional, private‑market‑exposed plumbing peers (via industry ETF/long‑short proxy) to isolate hospice upside while hedging sector cyclicality over 6–12 months.